In the tumor tissues, the cell surface marker of CSCs (CD44) was significantly depleted after VEDT treatment compared with vehicle as analyzed by both immunostaining (Figure 5A and 5B) and Western blot (Figure 4D) analyses. This evidence concerns the gene CD44 and neoplasm.